...
首页> 外文期刊>Journal of Veterinary Internal Medicine >Treatment of Severe Immune-Mediated Thrombocytopenia with Human IV Immunoglobulin in 5 Dogs
【24h】

Treatment of Severe Immune-Mediated Thrombocytopenia with Human IV Immunoglobulin in 5 Dogs

机译:人类IV免疫球蛋白治疗5只狗的严重免疫介导的血小板减少症

获取原文

摘要

Background : Glucocorticoids with or without other immunotherapy are the initial treatment of choice for dogs with severe immune-mediated thrombocytopenia (IMT). The majority of treated dogs will have improvements in platelet counts within 5 to 7 days of starting therapy, but complications from hemorrhage often occur before a response is seen. Human IV immunoglobulin (hIVIG) blocks Fc receptors on mononuclear phagocytic cells in dogs; it is used in people with idiopathic thrombocytopenic purpura.
机译:背景:有或没有其他免疫疗法的糖皮质激素是重症免疫介导的血小板减少症(IMT)犬的首选初始治疗方法。在开始治疗后的5到7天内,大多数接受治疗的狗的血小板计数都会有所改善,但是出血的并发症通常会在出现反应之前发生。人IV免疫球蛋白(hIVIG)阻断狗单核吞噬细胞上的Fc受体;它用于特发性血小板减少性紫癜的人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号